What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His primary scientific interests are in Chronic lymphocytic leukemia, Leukemia, Cancer research, Immunology and Molecular biology.
Chronic lymphocytic leukemia is a subfield of Internal medicine that he explores.
Thomas J. Kipps has included themes like Gastroenterology and Oncology in his Internal medicine study.
The study incorporates disciplines such as Gene rearrangement, Gene expression profiling, Lymphocyte, Pharmacology and CD20 in addition to Leukemia.
His work deals with themes such as Cell culture, breakpoint cluster region, Signal transduction and Chemokine receptor, which intersect with Cancer research.
In Molecular biology, Thomas J. Kipps works on issues like B cell, which are connected to Cell biology and Synovial membrane.
His most cited work include:
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia (4145 citations)
- miR-15 and miR-16 induce apoptosis by targeting BCL2. (2952 citations)
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines (2519 citations)
What are the main themes of his work throughout his whole career to date?
Thomas J. Kipps focuses on Chronic lymphocytic leukemia, Immunology, Internal medicine, Cancer research and Leukemia.
His Chronic lymphocytic leukemia study combines topics from a wide range of disciplines, such as Molecular biology and Antibody, B cell.
His Immunology study combines topics in areas such as CD154 and CD38.
The various areas that Thomas J. Kipps examines in his Internal medicine study include Gastroenterology and Oncology.
His Cancer research study incorporates themes from Cirmtuzumab, Apoptosis, Cancer and CD40.
His Leukemia research incorporates elements of Cytotoxic T cell, CD5, Hematology and microRNA.
He most often published in these fields:
- Chronic lymphocytic leukemia (60.16%)
- Immunology (31.81%)
- Internal medicine (30.80%)
What were the highlights of his more recent work (between 2017-2021)?
- Chronic lymphocytic leukemia (60.16%)
- Internal medicine (30.80%)
- Cancer research (33.26%)
In recent papers he was focusing on the following fields of study:
Chronic lymphocytic leukemia, Internal medicine, Cancer research, Ibrutinib and Oncology are his primary areas of study.
His Chronic lymphocytic leukemia study results in a more complete grasp of Leukemia.
His research in Leukemia intersects with topics in Hematology and Monoclonal.
His work on Venetoclax, Rituximab, Obinutuzumab and Progression-free survival as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His Cancer research research incorporates themes from Cirmtuzumab, Cancer, Cell and Stem cell.
His studies deal with areas such as Relapsed refractory, Chemoimmunotherapy, Ofatumumab and First line treatment as well as Oncology.
Between 2017 and 2021, his most popular works were:
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia (318 citations)
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions (205 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
His main research concerns Chronic lymphocytic leukemia, Internal medicine, Ibrutinib, Leukemia and Cancer research.
As part of one scientific family, Thomas J. Kipps deals mainly with the area of Chronic lymphocytic leukemia, narrowing it down to issues related to the Refractory, and often Tolerability.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Oncology.
His study in Ibrutinib is interdisciplinary in nature, drawing from both Adverse effect, Fludarabine and [email protected]
His studies in Leukemia integrate themes in fields like Monoclonal, Hematology, Disease, CD19 and Regulation of gene expression.
His biological study spans a wide range of topics, including Cell, Cell growth, RNA splicing, Cirmtuzumab and Bruton's tyrosine kinase.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
